Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Cg Oncology Inc (NASDAQ: CGON) was $37.04 for the day, up 0.38% from the previous closing price of $36.9. In other words, the price has increased by $0.38 from its previous closing price. On the day, 0.73 million shares were traded. CGON stock price reached its highest trading level at $37.655 during the session, while it also had its lowest trading level at $36.45.
Ratios:
Our analysis of CGON’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 22.15 and its Current Ratio is at 22.15. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $55.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 18 ’25 when Mulay James sold 19,112 shares for $39.01 per share. The transaction valued at 745,559 led to the insider holds 0 shares of the business.
Mulay James sold 3,574 shares of CGON for $139,350 on Sep 19 ’25. The Director now owns 0 shares after completing the transaction at $38.99 per share. On Sep 18 ’25, another insider, JAMES MULAY, who serves as the Director of the company, bought 35,441 shares for $37.72 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGON now has a Market Capitalization of 2824210688 and an Enterprise Value of 2164152320. For the stock, the TTM Price-to-Sale (P/S) ratio is 5134.93 while its Price-to-Book (P/B) ratio in mrq is 4.21. Its current Enterprise Value per Revenue stands at 3927.681 whereas that against EBITDA is -13.777.
Stock Price History:
The Beta on a monthly basis for CGON is 1.15, which has changed by 0.014238715 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, CGON has reached a high of $40.47, while it has fallen to a 52-week low of $14.80. The 50-Day Moving Average of the stock is 30.35%, while the 200-Day Moving Average is calculated to be 36.49%.
Shares Statistics:
CGON traded an average of 944.44K shares per day over the past three months and 1487420 shares per day over the past ten days. A total of 76.23M shares are outstanding, with a floating share count of 45.56M. Insiders hold about 40.24% of the company’s shares, while institutions hold 77.37% stake in the company. Shares short for CGON as of 1756425600 were 10232411 with a Short Ratio of 10.83, compared to 1753920000 on 11004280. Therefore, it implies a Short% of Shares Outstanding of 10232411 and a Short% of Float of 14.21.
Earnings Estimates
The dynamic stock of Cg Oncology Inc (CGON) is currently attracting attention from 9.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.44 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$1.77 and -$2.3 for the fiscal current year, implying an average EPS of -$2.07. EPS for the following year is -$2.14, with 9.0 analysts recommending between -$0.9 and -$3.8.
